Biolife Solutions (BLFS) 3.71 $BLFS
BioLife Solutions Closes $15.4 Million Public Offering and Converts $14.3 Million of Debt to Equity
PR Newswire - Tue Mar 25, 3:01PM CDT
BioLife Solutions, Inc. (OTCQB: BLFS) today announced that is has closed a public offering of units for gross proceeds of approximately $15.4 million at a price of $4.30 per unit, completed the conversion of $14.3 million of debt into equity and received approval to list its common stock on the NASDAQ Capital Market.
BioLife Solutions prices public offering of 3.6m units
M2 - Fri Mar 21, 6:45AM CDT
Cryopreservation solutions company BioLife Solutions (Other OTC:BLFS) reported on Thursday the planned sale of 3.6m units in a public offering.
BioLife Solutions Announces Pricing of $15.4 Million Public Offering
PR Newswire - Thu Mar 20, 8:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 3.6 million units for gross proceeds to the Company of approximately $15.4 million. Each unit consists of one share of the Company's common stock and one warrant, with each whole warrant exercisable for seven years to purchase one share of the Company's common stock at an exercise price of $4.75 per share. The units are being offered at a price of $4.30 per unit.
BioLife Solutions Announces Sponsorship of Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day
PR Newswire - Mon Mar 10, 5:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it is co-sponsoring the Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day, to be held March 26, 2014 at the Metropolitan Club in New York City.
2014 Joe Lieberman Connecticut Scholarship Fund Open for Student Applications through April 1
PR Newswire - Tue Feb 04, 7:15AM CST
Scholarship America announced today that the Joe Lieberman Connecticut Scholarship Fund, to assist outstanding high school seniors from Connecticut who plan to continue their education in college or vocational school programs, is now open for its second year of student applications.
BioLife Solutions To Be Issued New Biopreservation Patent
PR Newswire - Wed Jan 29, 10:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that the United States Patent and Trademark Office has notified the Company of a new patent, to be issued on February 4, 2014.
BioLife Solutions Announces 1:14 Reverse Stock Split
PR Newswire - Tue Jan 21, 3:30PM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that pursuant to the authorization previously granted by the Company's stockholders, the Company's Board of Directors (the "Board") has fixed 1-for-14 as the ratio for its previously announced reverse stock split. The Company anticipates that the reverse stock split will be effective at the market opening on January 29, 2014. The reverse stock split is intended to facilitate the listing of BioLife's common stock on the NASDAQ Capital Market®.
LifeSci Advisors Initiates Coverage of BioLife Solutions, Inc.
Marketwire - Thu Jan 09, 8:00AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of BioLife Solutions, Inc. (OTCBB: BLFS), a leading supplier of cGMP biopreservation media products for cells, tissues, and organs. The Company is focused on the development, manufacture, and marketing of biopreservation solutions used in the regenerative medicine, biobanking, and drug discovery markets. Current product offerings include HypoThermosol(R), CryoStor(R), and BloodStor(R), all pre-formulated, serum-free and protein-free biopreservation media and the SAVSU(R) line of precision thermal storage and shipping containers.
ConvergEx Prime Services Announces Record Growth in 2013
PR Newswire - Wed Jan 08, 10:00AM CST
ConvergEx Group, a leading provider of global brokerage and trading-related services, today announced that ConvergEx Prime Services continued its strong growth throughout 2013. In the past twelve months, ConvergEx Prime Services added a record number of new client accounts and saw its revenue grow more than 20% year over year. Additionally, the business reached a new high in clients' assets under management.
PA Banking and Securities Commissioner Elected to Investor Protection Trust
PR Newswire - Tue Jan 07, 8:58AM CST
IPT Board Welcomes Steven D. Irwin as Newest Trustee, Replacing Alabama's Joseph P. Borg
Global Managed Security Services Market
PR Newswire - Tue Jan 07, 8:50AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
BioLife Solutions Preliminary 2013 Revenue Grows to $9 Million
PR Newswire - Mon Jan 06, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $9.0 million for the full year 2013. This represents 58% growth over 2012, driven by increased shipments to a large contract-manufacturing customer and expanded adoption of CryoStor® freeze media and HypoThermosol® storage/shipping media in clinical trial stage cell-based regenerative medicine products and therapies.
Good News for Quidel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 3:35PM CST
Quidel Corp. received encouraging news when the FDA cleared 510(k) for the sale of its AmpliVue Group B Strep Assay.
BioLife Solutions Applies to List its Common Shares on the NASDAQ Capital Market®
PR Newswire - Mon Dec 16, 3:30PM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it has applied to list its common stock on the NASDAQ Capital Market. To support this listing, the Company also announced that its stockholders have authorized the Board of Directors (the "Board") to amend the Company's certificate of incorporation to effect a reverse stock split. The authorization provides the Board the discretion to effect a reverse stock split by a ratio of not less than one-for-four and not more than one-for-sixteen (1:4 up to 1:16, or anywhere in-between), while maintaining or reducing the number of authorized shares at any ratio. The proposed reverse stock split was approved by the holders of a majority of the Company's outstanding common stock by written consent in lieu of a special meeting. The Company has filed a preliminary information statement with the Securities and Exchange Commission to provide notice to its stockholders of the reverse stock split authorization. The Board has not yet determined whether to implement the reverse stock split or what ratio may be used.
BioLife Solutions CryoStor® Adopted by Discgenics for Use in Novel, Injectable Cellular Therapy for Degenerative Disc Disease
PR Newswire - Mon Dec 09, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that Discgenics, Inc., a privately-held Salt Lake City, UT development stage regenerative medicine company, has incorporated its CryoStor clinical grade cryopreservation freeze media in the development and potential commercialization of their Injectable Discogenic Cell Therapy (IDCT) product to treat patients suffering from low back pain associated with degenerative disc disease.
BioLife Solutions Appoints Raymond W. Cohen as Chairman and Joe Schick to Board of Directors
PR Newswire - Tue Nov 19, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has appointed a new chairman of the board and also a new director.
BioLife Solutions Announces $2.2 million Total Revenue for the Third Quarter of 2013
PR Newswire - Thu Nov 14, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced revenue for the third quarter of 2013 of $2.2 million, including core HypoThermosol® and CryoStor® product revenue of $1.0 million. This marked the first quarter that core revenue has exceeded $1.0 million. Total revenue was up 29% compared to the third quarter of 2012, and down 7% from the second quarter of 2013.
BioLife Solutions Makes Deloitte's 2013 Fast Technology 500(TM)
PR Newswire - Wed Nov 13, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has been named to the Deloitte 2013 Fast Technology 500 list of North American innovative, high growth technology companies.
BioLife Solutions Provides Update on Clinical Use of CryoStor® and HypoThermosol® Cell and Tissue Biopreservation Media Products
PR Newswire - Tue Sep 03, 5:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media products for cells and tissues, and contract aseptic media manufacturer, today published on its corporate website an updated listing of over 85 clinical trial and hospital -approved uses of its proprietary biopreservation media for cells and tissues. The Company's cGMP, protein-free, serum-free CryoStor freeze media and HypoThermosol storage and shipping media are currently incorporated as ancillary or excipient reagents used to store, ship, and freeze cell and tissue source material such as peripheral and cord blood, bone marrow, skeletal muscle tissue, skin, and cartilage, and also a great variety of final cell dose formulations currently in FDA and internationally approved clinical trials for treatment of heart disease, movement disorders, stroke, vision loss, neurologic disorders, various cancers, and other life-impacting and life-threatening diseases and disorders.
BioLife Solutions HypoThermosol® Embedded in Two Intercytex Clinical Trials of Cell-Based Wound Care
PR Newswire - Thu Aug 22, 5:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that its HypoThermosol, a pre-formulated, cGMP, serum-free, protein-free cell and tissue storage/shipping medium, is currently incorporated into on-going US and European clinical trials of ICX-RHY-013, a proprietary cell-based therapy developed by Intercytex Ltd. In both clinical trials, HypoThermosol is the vehicle solution containing the therapeutic cells administered to the patients, and is also the placebo solution in a control arm of the studies.
BioLife Solutions Closes $15.4 Million Public Offering and Converts $14.3 Million of Debt to Equity
PR Newswire - Tue Mar 25, 3:01PM CDT
BioLife Solutions, Inc. (OTCQB: BLFS) today announced that is has closed a public offering of units for gross proceeds of approximately $15.4 million at a price of $4.30 per unit, completed the conversion of $14.3 million of debt into equity and received approval to list its common stock on the NASDAQ Capital Market.
BioLife Solutions prices public offering of 3.6m units
M2 - Fri Mar 21, 6:45AM CDT
Cryopreservation solutions company BioLife Solutions (Other OTC:BLFS) reported on Thursday the planned sale of 3.6m units in a public offering.
BioLife Solutions Announces Pricing of $15.4 Million Public Offering
PR Newswire - Thu Mar 20, 8:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 3.6 million units for gross proceeds to the Company of approximately $15.4 million. Each unit consists of one share of the Company's common stock and one warrant, with each whole warrant exercisable for seven years to purchase one share of the Company's common stock at an exercise price of $4.75 per share. The units are being offered at a price of $4.30 per unit.
BioLife Solutions Announces Sponsorship of Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day
PR Newswire - Mon Mar 10, 5:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it is co-sponsoring the Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day, to be held March 26, 2014 at the Metropolitan Club in New York City.
2014 Joe Lieberman Connecticut Scholarship Fund Open for Student Applications through April 1
PR Newswire - Tue Feb 04, 7:15AM CST
Scholarship America announced today that the Joe Lieberman Connecticut Scholarship Fund, to assist outstanding high school seniors from Connecticut who plan to continue their education in college or vocational school programs, is now open for its second year of student applications.
BioLife Solutions To Be Issued New Biopreservation Patent
PR Newswire - Wed Jan 29, 10:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that the United States Patent and Trademark Office has notified the Company of a new patent, to be issued on February 4, 2014.
BioLife Solutions Announces 1:14 Reverse Stock Split
PR Newswire - Tue Jan 21, 3:30PM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that pursuant to the authorization previously granted by the Company's stockholders, the Company's Board of Directors (the "Board") has fixed 1-for-14 as the ratio for its previously announced reverse stock split. The Company anticipates that the reverse stock split will be effective at the market opening on January 29, 2014. The reverse stock split is intended to facilitate the listing of BioLife's common stock on the NASDAQ Capital Market®.
LifeSci Advisors Initiates Coverage of BioLife Solutions, Inc.
Marketwire - Thu Jan 09, 8:00AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of BioLife Solutions, Inc. (OTCBB: BLFS), a leading supplier of cGMP biopreservation media products for cells, tissues, and organs. The Company is focused on the development, manufacture, and marketing of biopreservation solutions used in the regenerative medicine, biobanking, and drug discovery markets. Current product offerings include HypoThermosol(R), CryoStor(R), and BloodStor(R), all pre-formulated, serum-free and protein-free biopreservation media and the SAVSU(R) line of precision thermal storage and shipping containers.
ConvergEx Prime Services Announces Record Growth in 2013
PR Newswire - Wed Jan 08, 10:00AM CST
ConvergEx Group, a leading provider of global brokerage and trading-related services, today announced that ConvergEx Prime Services continued its strong growth throughout 2013. In the past twelve months, ConvergEx Prime Services added a record number of new client accounts and saw its revenue grow more than 20% year over year. Additionally, the business reached a new high in clients' assets under management.
PA Banking and Securities Commissioner Elected to Investor Protection Trust
PR Newswire - Tue Jan 07, 8:58AM CST
IPT Board Welcomes Steven D. Irwin as Newest Trustee, Replacing Alabama's Joseph P. Borg
Global Managed Security Services Market
PR Newswire - Tue Jan 07, 8:50AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
BioLife Solutions Preliminary 2013 Revenue Grows to $9 Million
PR Newswire - Mon Jan 06, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $9.0 million for the full year 2013. This represents 58% growth over 2012, driven by increased shipments to a large contract-manufacturing customer and expanded adoption of CryoStor® freeze media and HypoThermosol® storage/shipping media in clinical trial stage cell-based regenerative medicine products and therapies.
Good News for Quidel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 3:35PM CST
Quidel Corp. received encouraging news when the FDA cleared 510(k) for the sale of its AmpliVue Group B Strep Assay.
BioLife Solutions Applies to List its Common Shares on the NASDAQ Capital Market®
PR Newswire - Mon Dec 16, 3:30PM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it has applied to list its common stock on the NASDAQ Capital Market. To support this listing, the Company also announced that its stockholders have authorized the Board of Directors (the "Board") to amend the Company's certificate of incorporation to effect a reverse stock split. The authorization provides the Board the discretion to effect a reverse stock split by a ratio of not less than one-for-four and not more than one-for-sixteen (1:4 up to 1:16, or anywhere in-between), while maintaining or reducing the number of authorized shares at any ratio. The proposed reverse stock split was approved by the holders of a majority of the Company's outstanding common stock by written consent in lieu of a special meeting. The Company has filed a preliminary information statement with the Securities and Exchange Commission to provide notice to its stockholders of the reverse stock split authorization. The Board has not yet determined whether to implement the reverse stock split or what ratio may be used.
BioLife Solutions CryoStor® Adopted by Discgenics for Use in Novel, Injectable Cellular Therapy for Degenerative Disc Disease
PR Newswire - Mon Dec 09, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that Discgenics, Inc., a privately-held Salt Lake City, UT development stage regenerative medicine company, has incorporated its CryoStor clinical grade cryopreservation freeze media in the development and potential commercialization of their Injectable Discogenic Cell Therapy (IDCT) product to treat patients suffering from low back pain associated with degenerative disc disease.
BioLife Solutions Appoints Raymond W. Cohen as Chairman and Joe Schick to Board of Directors
PR Newswire - Tue Nov 19, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has appointed a new chairman of the board and also a new director.
BioLife Solutions Announces $2.2 million Total Revenue for the Third Quarter of 2013
PR Newswire - Thu Nov 14, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced revenue for the third quarter of 2013 of $2.2 million, including core HypoThermosol® and CryoStor® product revenue of $1.0 million. This marked the first quarter that core revenue has exceeded $1.0 million. Total revenue was up 29% compared to the third quarter of 2012, and down 7% from the second quarter of 2013.
BioLife Solutions Makes Deloitte's 2013 Fast Technology 500(TM)
PR Newswire - Wed Nov 13, 5:00AM CST
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has been named to the Deloitte 2013 Fast Technology 500 list of North American innovative, high growth technology companies.
BioLife Solutions Provides Update on Clinical Use of CryoStor® and HypoThermosol® Cell and Tissue Biopreservation Media Products
PR Newswire - Tue Sep 03, 5:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media products for cells and tissues, and contract aseptic media manufacturer, today published on its corporate website an updated listing of over 85 clinical trial and hospital -approved uses of its proprietary biopreservation media for cells and tissues. The Company's cGMP, protein-free, serum-free CryoStor freeze media and HypoThermosol storage and shipping media are currently incorporated as ancillary or excipient reagents used to store, ship, and freeze cell and tissue source material such as peripheral and cord blood, bone marrow, skeletal muscle tissue, skin, and cartilage, and also a great variety of final cell dose formulations currently in FDA and internationally approved clinical trials for treatment of heart disease, movement disorders, stroke, vision loss, neurologic disorders, various cancers, and other life-impacting and life-threatening diseases and disorders.
BioLife Solutions HypoThermosol® Embedded in Two Intercytex Clinical Trials of Cell-Based Wound Care
PR Newswire - Thu Aug 22, 5:00AM CDT
BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that its HypoThermosol, a pre-formulated, cGMP, serum-free, protein-free cell and tissue storage/shipping medium, is currently incorporated into on-going US and European clinical trials of ICX-RHY-013, a proprietary cell-based therapy developed by Intercytex Ltd. In both clinical trials, HypoThermosol is the vehicle solution containing the therapeutic cells administered to the patients, and is also the placebo solution in a control arm of the studies.
